Evan Feinberg is a founder and CEO with 11 years of experience building AI-first drug discovery platforms, leading Genesis Therapeutics from a Stanford PhD thesis to a venture-backed full-stack biotech. He combines deep technical expertise in graph convolutional neural networks and molecular property prediction (developed under Vijay Pande at Stanford) with hands-on industry experience as a deep learning consultant for Merck and contributions to the influential DeepChem open-source project. Trained in applied physics at Yale and computational biophysics at Schrödinger, he bridges rigorous physical science intuition with practical ML engineering to accelerate molecule design. Notably, his work spans both research-grade model innovation and production-oriented data and featurization improvements that make advanced algorithms usable in real drug programs.
11 years of coding experience
Bachelor of Science - BS, Bachelor of Science - BS at Yale University
Doctor of Philosophy - PhD, Doctor of Philosophy - PhD at Stanford University
Democratizing Deep-Learning for Drug Discovery, Quantum Chemistry, Materials Science and Biology
Role in this project:
Data Scientist
Contributions:63 commits, 10 PRs, 2 pushes in 1 year 8 months
Contributions summary:Evan contributed to data processing and model development within the deepchem repository, focusing on the domain of drug discovery, quantum chemistry, and biology. Their commits addressed data-processing bugs, compatibility with 3D grid features, and improvements to featurization functionality. They also appear to be working on data munging efficiency and building functionality related to the use of machine learning for tasks such as the use of tox21.
Find and Hire Top DevelopersWe’ve analyzed the programming source code of over 60 million software developers on GitHub and scored them by 50,000 skills. Sign-up on Prog,AI to search for software developers.
Request Free Trial
Evan Feinberg - Founder And CEO at Genesis Therapeutics